E-LIB Suche - Ergebnisse für: Pro B

1

Outcomes of contemporary novel agent incorporation in relap..:

Tolu, S. S. ; Seshadri, M. R. ; Chen, Z....
Hematological Oncology. 41 (2023) S2 - p. 511-512 , 2023

Link: https://doi.org/10.1002/..

2

ETCTN P10500: PHASE 1/EXPANSION STUDY OF TAZEMETOSTAT PLUS ..:

Amengual, J. E. ; Shyr, Y. ; Durecki, D....
Hematological Oncology. 41 (2023) S2 - p. 833-834 , 2023

Link: https://doi.org/10.1002/..

3

Duvelisib in patients with relapsed/refractory peripheral T..:

Mehta‐Shah, N. ; Jacobsen, E. D. ; Zinzani, P. L....
Hematological Oncology. 41 (2023) S2 - p. 499-500 , 2023

Link: https://doi.org/10.1002/..

4

The ECHELON-2 Trial: 5-year results of a randomized, phase ..:

Horwitz, S. ; O'Connor, O.A. ; Pro, B....
Annals of Oncology. 33 (2022) 3 - p. 288-298 , 2022

Link: https://doi.org/10.1016/..

5

P1172: DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIP..:

Zinzani, P. L. ; Zain, J. ; Mead, M....
HemaSphere. 6 (2022) - p. 1058-1059 , 2022

Link: https://doi.org/10.1097/..

6

PRIMARY EXTRANODAL FOLLICULAR LYMPHOMA IN A LARGE RETROSPEC..:

Conconi, A. ; Vannata, B. ; Janikova, A....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

7

MULTI‐CENTER PHASE II STUDY OF ROMIDEPSIN PLUS LENALIDOMIDE..:

Ruan, J. ; Zain, J. M ; Palmer, B....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

8

PO-1285: Gender disparity among United States academic onco..:

Chowdhary, M. ; Chowdhary, A. ; Royce, T....
Radiotherapy and Oncology. 152 (2020) - p. S677-S678 , 2020

Link: https://doi.org/10.1016/..

9

TIME TO NEXT TREATMENT IN PATIENTS WITH PREVIOUSLY TREATED ..:

Kim, Y.H. ; Ortiz‐Romero, P.L. ; Pro, B....
Hematological Oncology. 37 (2019) S2 - p. 285-286 , 2019

Link: https://doi.org/10.1002/..

10

Radiation Oncology Education for Medical Oncology Fellowshi..:

Paudel, N. ; Pro, B. ; Boddy, C....
International Journal of Radiation Oncology*Biology*Physics. 102 (2018) 3 - p. e395 , 2018

Link: https://doi.org/10.1016/..

11

GSK‐3ß INHIBITOR, 9‐ING‐41 REDUCES CELL VIABILITY AND HALTS..:

Karmali, R. ; Chukkapalli, V. ; Pro, B....
Hematological Oncology. 35 (2017) S2 - p. 400-402 , 2017

Link: https://doi.org/10.1002/..

12

Utility of18fluoro-deoxyglucose positron emission tomograph..:

Horwitz, S. ; Coiffier, B. ; Foss, F....
Annals of Oncology. 26 (2015) 4 - p. 774-779 , 2015

Link: https://doi.org/10.1093/..

13

Pre-transplant positive PET/Gallium scans predict poor outc..:

Jabbour, E. ; Hosing, C. ; Pro, B....
Biology of Blood and Marrow Transplantation. 12 (2006) 2 - p. 114-115 , 2006

Link: https://doi.org/10.1016/..

14

The ECHELON-2 Trial: 5-year results of a randomized, phase ..:

Horwitz, S ; O'connor, O. A ; Pro, B...
10.1016/j.annonc.2021.12.002. , 2023

Link: https://hdl.handle.net/2..

15

The ECHELON-2 Trial: 5-year results of a randomized, phase ..:

Horwitz S ; O'Connor O. A ; Pro B...
info:eu-repo/semantics/altIdentifier/pmid/34921960. , 2022

Link: https://hdl.handle.net/1..